Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

TAMPA, FLA. (PRWEB) JULY 01, 2021 — Psilera Inc., formerly Psilera Bioscience (“Psilera”), a Florida-based biotechnology company specializing in the clinical development of psychedelics and analogues, has secured $2,500,000 in a non-brokered series of seed preferred funding (the “Financing”). The influx of funding was led by Iter Investments with participation from Baird Inc., JLS Fund, Receptor…

Source